|
2022 Conference Publication Appendiceal neuroendocrine tumours in individuals under the age of 50 years: A population-based study from Queensland, AustraliaMoorhead, William, Youl, Philippa, Moore, Julie and Wyld, David (2022). Appendiceal neuroendocrine tumours in individuals under the age of 50 years: A population-based study from Queensland, Australia. HOBOKEN: WILEY. |
|
2022 Conference Publication Salvage 177Lu-dotatate therapy in patients with progressive metastatic neuroendocrine tumorsHoe, Hui Jing and Wyld, David (2022). Salvage 177Lu-dotatate therapy in patients with progressive metastatic neuroendocrine tumors. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Electr Network, Jun 03-07, 2022. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. |
|
2022 Conference Publication Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: <SUP>177</SUP>Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) and capecitabine plus temozolomide (CAPTEM) for pancreas and midgut neuroendocrine tumours (pNETS, mNETS)-Final resultsPavlakis, Nick, Ransom, David Turner, Wyld, David, Sjoquist, Katrin Marie, Wilson, Kate, Gebski, Val, Murray, James, Kiberu, Andrew Ddembe, Burge, Matthew E., Macdonald, William, Roach, Paul, Pattison, David A., Butler, Patrick, Price, Timothy Jay, Michael, Michael, Lawrence, Benjamin James, Bailey, Dale L., Leyden, Simone, Zalcberg, John Raymond and Turner, Harvey (2022). Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) and capecitabine plus temozolomide (CAPTEM) for pancreas and midgut neuroendocrine tumours (pNETS, mNETS)-Final results. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Electr Network, Jun 03-07, 2022. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. |
|
2021 Conference Publication 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with somatostatin-expressing neuroendocrine tumors: a real-world retrospective review of efficacy and safety from an Australian tertiary cancer CenterNalder, Mark, Ladwa, Rahul, Raina, Anant, Burge, Matthew E., Love, Amanda, Pattison, David A., Ramsay, Stuart and Wyld, David (2021). 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with somatostatin-expressing neuroendocrine tumors: a real-world retrospective review of efficacy and safety from an Australian tertiary cancer Center. 2021 ASCO Annual Meeting I, Virtual, 4-8 June 2021. Alexandria, VA USA: American Society of Clinical Oncology. doi: 10.1200/jco.2021.39.15_suppl.e16198 |
|
2020 Conference Publication P3BEP (ANZUP 1302): an international randomized phase III trial of accelerated versus standard BEP chemotherapy for adult and pediatric male and female patients with intermediate and poor-risk metastatic germ cell tumors (GCTs)Subramaniam, Shalini, Toner, Guy C., Stockler, Martin R., Martin, Andrew James, Pashankar, Farzana D., Frazier, A. Lindsay, Mazhar, Danish, Ford, Kate, Walpole, Euan Thomas, Stevanovic, Amanda Gwendolyn, Wyld, David, Troon, Simon, Hanning, Fritha J., Birtle, Alison Jane, Wheater, Matthew James, Huddart, Robert A., White, Jeff D., Spunt, Sheri L. and Grimison, Peter S. (2020). P3BEP (ANZUP 1302): an international randomized phase III trial of accelerated versus standard BEP chemotherapy for adult and pediatric male and female patients with intermediate and poor-risk metastatic germ cell tumors (GCTs). Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO), San Francisco, CA USA, 13-15 February 2020. Alexandria, VA: American Society of Clinical Oncology. |
|
2020 Conference Publication Insights into the practice patterns, challenges and the role of a shared care model in the management of neuroendocrine (NET) patients in the communityRadhika, Y., Chan, D., Thawer, A., Lo, D., Singh, S. and Wyld, D. (2020). Insights into the practice patterns, challenges and the role of a shared care model in the management of neuroendocrine (NET) patients in the community. 17th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Electr Network, 11-13 March 2020. Basel, Switzerland: S. Karger. |
|
2019 Conference Publication Ontario oncologists' perspectives on addressing potential barriers in the management of patients with neuroendocrine tumorsFingrut, Warren, Yelamanchili, Radhika, Thawer, Alia, Chan, David, Wyld, David, Singh, Simron and Lo, Dorothy (2019). Ontario oncologists' perspectives on addressing potential barriers in the management of patients with neuroendocrine tumors. 11th Annual Meeting of the North American Neuroendocrine Tumor Society, Seattle, Washington, October 4-6, 2018. Philadelphia, PA, United States: Lippincott Williams & Wilkins. doi: 10.1097/MPA.0000000000001250 |
|
2019 Conference Publication Practice Patterns, Challenges, and the Role of a Shared Care Model in the Management of Neuroendocrine (NET) PatientsYelamanchili, Radhika, Thawer, Alia, Chan, David, Lo, Dorothy, Singh, Simron, Fingrut, Warren and Wyld, David (2019). Practice Patterns, Challenges, and the Role of a Shared Care Model in the Management of Neuroendocrine (NET) Patients. 11th Annual Meeting of the North American Neuroendocrine Tumor Society, Seattle, Washington, October 4-6, 2018. Philadelphia, PA, United States: Lippincott Williams & Wilkins. doi: 10.1097/MPA.0000000000001250 |
|
2019 Conference Publication Royal Brisbane MedicalOncology Clinic Activity ReviewKuchel, Anna, Kermond, Anna, Lonton, Jennifer, Wyld, David and Eastgate, Melissa (2019). Royal Brisbane MedicalOncology Clinic Activity Review. COSA's 46th Annual Scientific Meeting, Urological cancer; Age and gender in cancer practice; Digital health in cancer, Adelaide, SA Australia, 12–14 November 2019. Chichester, West Sussex United Kingdom: Wiley-Blackwell. |
|
2018 Conference Publication Implementing a highly accessible model of screening and assessment in geriatric oncology: Our experienceBryant, Geoffrey, Thaker, Darshit, Wyld, David, Leach, Justine, Wheatley, Hermione and Garth, Vanessa (2018). Implementing a highly accessible model of screening and assessment in geriatric oncology: Our experience. HOBOKEN: WILEY. |
|
2018 Conference Publication Is survival improving for patients diagnosed with small intestinal neuroendocrine tumours in Queensland?Moore, Julie, Dunn, Nathan, Tran, Nancy and Wyld, David (2018). Is survival improving for patients diagnosed with small intestinal neuroendocrine tumours in Queensland?. HOBOKEN: WILEY. |
|
2018 Conference Publication A randomized controlled study comparing treatment of gastro-entero-pancreatic neuroendocrine tumors (GEPNET) with 177Lu-DOTATATE alone and in combination with capecitabineVan der Zwan, W., Wyld, D., Brabander, T., Teunissen, J., Kam, B., MacFarlane, D., Krenning, E., Kwekkeboom, D. and de Herder, W. (2018). A randomized controlled study comparing treatment of gastro-entero-pancreatic neuroendocrine tumors (GEPNET) with 177Lu-DOTATATE alone and in combination with capecitabine. 15th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Barcelona, Spain, 7 - 9 March 2018. Basel, Switzerland: S. Karger AG. |
|
2018 Conference Publication How the rare see their care: Perceptions of care and patient reported outcomes in people living with neuroendocrine tumoursWyld, D., Burge, M., Dumbrava, M., Callum, J., Neale, R. and Beesley, V. (2018). How the rare see their care: Perceptions of care and patient reported outcomes in people living with neuroendocrine tumours. Victorian Cancer Survivorship Conference, Melbourne, Australia, 8 -9 February 2018. |
|
2018 Conference Publication Validation of Abbreviated 177Lu-DOTATATE Renal and Lesional Dosimetry Protocol using Quantitative SPECTGoodman, Steven , Patford, Shaun , Ladwa, Rahul , Smith, Jye , Wyld, David and Pattison, David A. (2018). Validation of Abbreviated 177Lu-DOTATATE Renal and Lesional Dosimetry Protocol using Quantitative SPECT. 12th Congress of the World Federation of Nuclear Medicine and Biology., Melbourne Australia, 20-24 April 2018. |
|
2018 Conference Publication Pretherapeutic predictors of tumor absorbed dosimetry in radionuclide therapy for metastatic neuroendocrine tumorsLadwa, R., Pattison, D., Smith, J., Goodman, S., Burg, M., Rose, S., Dowson, N. and Wyld, D. (2018). Pretherapeutic predictors of tumor absorbed dosimetry in radionuclide therapy for metastatic neuroendocrine tumors. 15th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Barcelona, Spain, 7-9 March 2018. Basel, Switzerland: S. Karger AG. |
|
2018 Conference Publication Colorectal cancer patient reported outcomes: putting theory into practiceBryant, Geoffrey, Eastgate, Melissa, Wyld, David, Burge, Matthew, Thaker, Darshit and Busato, Matthew (2018). Colorectal cancer patient reported outcomes: putting theory into practice. COSA's 45th Annual Scientific Meeting, Mesothelioma and Gastro‐Intestinal Cancers: Technology and Genomics, Perth Convention and Exhibition Centre, 13–15 November 2018. Chichester, West Sussex, United Kingdom: Wiley-Blackwell. |
|
2018 Conference Publication How the Rare See Their Care: Perceptions of Care and Patient Reported Outcomes in People Living with Neuroendocrine TumorsWyld, D., Burge, M., Dumbrava, M., Callum, J., Neale, R. and Beesley, V. (2018). How the Rare See Their Care: Perceptions of Care and Patient Reported Outcomes in People Living with Neuroendocrine Tumors. 15th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Barcelona, Spain, 7-9 March 2018. Basel, Switzerland: Karger. doi: 10.1159/000487699 |
|
2018 Conference Publication Dietary patterns and attitudes in cancer survivorsLee, Shu Fen , Wyld, David , Eastgate, Melissa and Brown, Teresa (2018). Dietary patterns and attitudes in cancer survivors. Victorian Cancer Survivorship Conference, Melbourne, Australia, 8-9 February 2018. |
|
2018 Conference Publication Positron Emission Tomography (PET) predictors of tumor response to Peptide Receptor Radionuclide Therapy (PRRT) in metastatic Neuroendocrine Tumors (NET)Ladwa, R., Pattison, D., Smith, J., Goodman, S., Burge, M., Rose, S., Dowson, N. and Wyld, D. (2018). Positron Emission Tomography (PET) predictors of tumor response to Peptide Receptor Radionuclide Therapy (PRRT) in metastatic Neuroendocrine Tumors (NET). 15th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Barcelona, Spain, 7-9 March 2018. Basel, Switzerland: S. Karger AG. |
|
2018 Conference Publication Neuroendocrine Neoplasm Trends Over 32 Years in Queensland, AustraliaWan, Mark H., Moore, Julie and Wyld, David K. (2018). Neuroendocrine Neoplasm Trends Over 32 Years in Queensland, Australia. Princess Margaret Cancer Conference. Accelerating Precision Medicine 2018, Toronto Canada, January 19 2018. |
